<DOC>
	<DOCNO>NCT01023477</DOCNO>
	<brief_summary>The purpose study test hypothesis chloroquine reduce ability ductal carcinoma situ ( DCIS ) survive spread . Participants receive either chloroquine standard dose ( 500mg/week ) chloroquine low dose ( 250mg/week ) 1 month prior surgical removal tumor .</brief_summary>
	<brief_title>Study Efficacy Chloroquine Treatment Ductal Carcinoma Situ ( The PINC Trial )</brief_title>
	<detailed_description>The purpose study test hypothesis inhibit autophagy pathway DCIS reduce capacity DCIS survive invade . The study examine safety effectiveness neoadjuvant chloroquine administration one month period patient low , intermediate grade , high grade DCIS . We evaluate whether treatment reduce capacity DCIS neoplastic cell , exist within duct , survive , induce lesion regression , kill invasive DCIS progenitor cell .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Patients must tissue diagnosis low , intermediate high grade ductal carcinoma situ ductal carcinoma situ microinvasion . Patients ductal carcinoma situ undergo either lumpectomy/radiation mastectomy . Patients must female least 18 year age . Patients must sign tissue acquisition consent minimum , adequate sample primary fresh tissue blood available use study . No history previous invasive cancer last five year exception minimally invasive nonmelanoma skin cancer . Normal liver function base Liver Function Tests ( Total Bilirubin AST &lt; 1.5 X Upper Limit Normal ) . Normal WBC ( 3.510.8 x 103µL ) , PLT ( 140400 x 103µL ) , HCT ( 3752 % ) Potassium within normal range 3.55.3 mEq/L Adequate renal sufficiency ( serum creatinine &lt; 1.5 mg/dL ) . ECOG performance status 02 . Are able swallow retain oral medication . No underlying ocular/retinal pathology . No medically document preexist auditory damage . Subjects willing abstain use hormonal therapy ( e.g . hormone replacement therapy , oral contraceptive pill , hormonecontaining IUDs , Estring ) chronic NSAID 's duration study ( chronic use NSAID 's defined frequency &gt; 3 times/week two week per year include low dose aspirin ) . Subjects childbearing potential must agree use adequate contraception ( total abstinence ( sexual intercourse ) , use condom spermicide sterilization surgery , include tubal ligation ( tubes tie ) hysterectomy ( removal uterus womb ) ) prior study entry duration study treatment phase . Should woman become pregnant suspect pregnant participating study , inform study physician immediately . If subject childbearing potential ( woman consider childbearing potential least one year postmenopausal and/or surgically sterile ) , must document negative serum urine pregnancy test start treatment . Patients prior history chemotherapy , hormonal ablation therapy and/or radiation therapy . History invasive cancer previous 5 year minimally invasive nonmelanoma skin cancer . Patient desire participate study . Inability consent . Current recent pregnancy ( within 12 month ) , Current use hormonecontaining form birth control implant ( i.e . Norplants , injectables ( i.e . depoprovera ) Currently lactate . Patients history renal hepatic insufficiency . Current diagnosis depression , include treatment SSRI . History prior treatment chloroquine malaria within past 24 month . History allergic reaction quinalones chloroquine . Active diagnosis psoriasis currently receive treatment psoriasis . History porphyria . History known Glucose6Phosphate Dehydrogenase ( G6PD ) deficiency . Alcoholism hepatic disease . History epilepsy seizure past 20 year . History deep vein thrombosis pulmonary embolism . History HIV disease and/or treatment antiHIV agent . Receiving concurrent treatment prohibit medication ( refer Table 1 detail prohibit medication ) ; Examples include : ampicillin , antacid , cimetidine , cyclosporine , kaolin , magnesium trisilicate , coumarintype anticoagulant , macrolide antibiotic ( e.g. , clarithromycin , isoniazid , erythromycin ) , antiHIV agent ( e.g. , ritonavir delavirdine ) , antidepressant ( e.g . fluoxetine fluvoxamine ) , calcium channel blocker ( e.g . verapamil diltiazem ) , steroids modulators ( e.g. , gestodene , raloxifene , mifepristone ) , several herbal dietary component ( e.g . bergamottin glabridin ) . Used investigational drug within 30 day 5 halflives , whichever longer , precede first dose study medication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Carcinoma , Intraductal , Noninfiltrating</keyword>
	<keyword>Ductal Carcinoma In Situ</keyword>
	<keyword>DCIS</keyword>
	<keyword>Carcinoma , Intraductal</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumors</keyword>
	<keyword>chloroquine</keyword>
	<keyword>autophagy</keyword>
	<keyword>Autophagic Cell Death</keyword>
	<keyword>Autophagocytosis</keyword>
	<keyword>Programmed Cell Death , Type II</keyword>
	<keyword>Autophagy , Cellular</keyword>
	<keyword>Autophagic Programmed Cell Death</keyword>
</DOC>